Drug Trial Radar · NCT07752875
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Dec 1, 2026
Primary completion
Oct 31, 2032
Study completion Apr 30, 2033
Sponsor
- Lead sponsor
- LG ChemIndustry
- Sponsor type
- Industry
- First posted
- Aug 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C mutation
Conditions
- Ovarian Cancer
- Small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Colorectal Cancer
- Esophageal Cancer
- Breast Cancer
- Endometrial Cancer
- Head and Neck Cancer
- Pancreatic Cancer
- Locally Advanced Unresectable or Metastatic Solid Tumor
Interventions
LG00313112Drug
LG00313112 will be administered orally once daily (QD)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of participants with dose-limiting toxicities (DLTs)Time frame: Up to 21 days after treatment
- Phase 1: Frequency of treatment-emergent adverse events (TEAEs)Time frame: Up to 12 months after treatment initiation
- Phase 1: Frequency of serious adverse events (SAEs)Time frame: Up to 12 months after treatment initiation
- Phase 2: objective response rate (ORR)Time frame: Up to 12 months after treatment initiation
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.